AstraZeneca Rethinking Blockbuster Model After Exanta “Not Approvable”
Executive Summary
FDA's "not approvable" decision for AstraZeneca's Exanta highlights the increasing difficulty of developing drugs with blockbuster potential while satisfying strict regulatory standards